Oncotarget

Research Papers:

The GSK3β inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level

Natthakan Thongon _, Ilaria Castiglioni, Chiara Zucal, Elisa Latorre, Vito D'Agostino, Inga Bauer, Michael Pancher, Alberto Ballestrero, Georg Feldmann, Alessio Nencioni and Alessandro Provenzani

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:26551-26566. https://doi.org/10.18632/oncotarget.8437

Metrics: PDF 2394 views  |   HTML 2691 views  |   ?  


Abstract

Natthakan Thongon1,*, Ilaria Castiglioni2,*, Chiara Zucal1, Elisa Latorre1, Vito D’Agostino1, Inga Bauer3, Michael Pancher4, Alberto Ballestrero3, Georg Feldmann5, Alessio Nencioni3, Alessandro Provenzani1

1Laboratory of Genomic Screening, Centre for Integrative Biology, University of Trento, Trento, Italy

2Laboratory of Gene Expression and Muscular Dystrophy, San Raffaele Scientific Institute, Milan, Italy

3Department of Internal Medicine, University of Genoa, Genoa, Italy

4High Throughput Screening Facility, Centre for Integrative Biology, University of Trento, Trento, Italy

5Laboratory of Pancreatic Cancer Translational Research, Clinic University of Bonn, Bonn, Germany

*These authors have contributed equally to this work

Correspondence to:

Alessandro Provenzani, email: [email protected]

Keywords: YAP, EMT, CTGF, PDAC, bisindolylmaleimides

Received: August 28, 2015    Accepted: March 06, 2016    Published: March 28, 2016

ABSTRACT

The Yes-associated protein, YAP, is a transcriptional co-activator, mediating the Epithelial to Mesenchymal Transition program in pancreatic ductal adenocarcinoma (PDAC). With the aim to identify compounds that can specifically modulate YAP functionality in PDAC cell lines, we performed a small scale, drug-based screening experiment using YAP cell localization as the read-out. We identified erlotinib as an inducer of YAP cytoplasmic localization, an inhibitor of the TEA luciferase reporter system and the expression of the bona fide YAP target gene, Connective Tissue Growth Factor CTGF. On the other hand, BIS I, an inhibitor of PKCδ and GSK3β, caused YAP accumulation into the nucleus. Activation of β-catenin reporter and interfering experiments show that inhibition of the PKCδ/GSK3β pathway triggers YAP nuclear accumulation inducing YAP/TEAD transcriptional response. Inhibition of GSK3β by BIS I reduced the expression levels of SMADs protein and reduced YAP contribution to EMT. Notably, BIS I reduced proliferation, migration and clonogenicity of PDAC cells in vitro, phenocopying YAP genetic down-regulation. As shown by chromatin immunoprecipitation experiments and YAP over-expressing rescue experiments, BIS I reverted YAP-dependent EMT program by modulating the expression of the YAP target genes E-cadherin, vimentin, CTGF and of the newly identified target, CD133. In conclusion, we identified two different molecules, erlotinib and BIS I, modulating YAP functionality although via different mechanisms of action, with the second one specifically inhibiting the YAP-dependent EMT program in PDAC cell lines.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8437